Philip Ashton-Rickardt
Chief Tech/Sci/R&D Officer at SIGILON THERAPEUTICS, INC.
Net worth: - $ as of 30/07/2023
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rogério Vivaldi Coelho | M | 60 | 6 years | |
| Josias Fantato De Pontes | M | 58 | 5 years | |
| Matthew P. Kowalsky | M | 52 | 5 years | |
| Michael Thompson | M | - | 1 years | |
| Philip Johnson | M | 59 | 1 years | |
| Omid Veiseh | M | - | 9 years | |
| Jamie Murphy | M | - | - | |
| Bernd Kullmann | M | - | - | |
| Qing Sarah Yuan | M | 53 | 2 years | |
| Robert Windsor | M | - | 3 years | |
| Gordon Brooks | M | - | 1 years | |
| Arturo Jose Vegas | M | - | 9 years | |
| Nicholas G. Hatsopoulos | M | 62 |
The University of Chicago
| 22 years |
| José Oberholzer | M | - | 9 years | |
| Michael Polsky | M | - |
The University of Chicago
| 21 years |
| Melissa Gilliam | M | 58 |
The University of Chicago
| 19 years |
| Stephen B. H. Kent | M | 79 |
The University of Chicago
| 23 years |
| Javier H. Rubinstein | M | - |
The University of Chicago
| 28 years |
| George D. Behrakis | M | - |
AZTherapies, Inc.
 AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 5 years |
| Noah Gottdiener | M | 67 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 4 years |
| Thierry Porté | M | 67 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 4 years |
| Michael Walter Vannier | M | 75 |
The University of Chicago
| 20 years |
| Chris Anderson | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Cole | M | 63 | 8 years | |
| Daniel Anderson | M | - | 6 years | |
| Glenn M. Reicin | M | 59 | 2 years | |
| Michael Frankel | M | 56 |
The University of Chicago
| 9 years |
| Stephen Oesterle | M | 73 | 7 years | |
| Luis Garicano Gabilondo | M | - |
The University of Chicago
| 4 years |
| Bilal Memon | M | - |
The University of Chicago
| 8 years |
| Robert Ruffolo | M | 74 | 7 years | |
| Robert Stockton | M | - |
The University of Chicago
| 4 years |
| Timothy Doede | M | - |
The University of Chicago
| 4 years |
| John Cox | M | 61 | 4 years | |
| Matthew McAviney | M | - |
The University of Chicago
| 9 years |
| Hoossam Malek | M | - |
The University of Chicago
| 3 years |
| Kavita Patel | M | 50 | 3 years | |
| Eric Shaff | M | 48 | 6 years | |
| Jason L. Wyman | M | - |
The University of Chicago
| 8 years |
| Justin Kern | M | - |
The University of Chicago
| 10 years |
| Sonia Marciano | M | 61 |
The University of Chicago
| 2 years |
| Martha Rook | F | 53 | 4 years | |
| Taylor Feehley | M | - |
The University of Chicago
| 10 years |
| Feng Li | M | 48 |
The University of Chicago
| 3 years |
| Jay Mohr | M | - |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 1 years |
| Amer Hasan | M | - |
The University of Chicago
| 7 years |
| Brooke Story | F | 52 | 1 years | |
| Lukasz Pomorski | M | - |
The University of Chicago
| 3 years |
| Daniel Nurmi | M | - |
The University of Chicago
| 1 years |
| Charles Hachten | M | - |
The University of Chicago
| 9 years |
| Alberto Ramos | M | - |
The University of Chicago
| 5 years |
| Peishan Tan | M | - |
The University of Chicago
| 5 years |
| David Cheng | M | - |
The University of Chicago
| 4 years |
| David Edward Kuenzi | M | - |
The University of Chicago
| 4 years |
| James Crown | M | 70 |
The University of Chicago
| 18 years |
| Marc M. P. de Garidel | M | 66 |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | 1 years |
| Gerald S. Tannenbaum | M | - |
The University of Chicago
| 7 years |
| Meridith Alin | F | - |
The University of Chicago
| 4 years |
| Tim Anderson | M | - |
The University of Chicago
| 5 years |
| Peter Kagan | M | 73 |
The University of Chicago
| 3 years |
| Samarth Chandra | M | - |
The University of Chicago
| 4 years |
| Alexander Blades | M | 54 |
The University of Chicago
| 3 years |
| Carlos Pedro Salas | M | 52 |
The University of Chicago
| 3 years |
| Matthew Tyler Brennan | M | - |
The University of Chicago
| 4 years |
| Zach Egan | M | 56 |
The University of Chicago
| 1 years |
| Hersh Shintre | M | - |
The University of Chicago
| 4 years |
| Deya Corzo | M | 57 | 3 years | |
| Richard John Moroney | M | 58 |
The University of Chicago
| 2 years |
| Karl Israelsen | M | - |
The University of Chicago
| 3 years |
| Thomas Stout | M | 46 |
The University of Chicago
| 2 years |
| Randall Mehl | M | 56 |
The University of Chicago
| 2 years |
| Todd Eugene Petzel | M | - |
The University of Chicago
| 6 years |
| Martha Heitmann | F | - |
The University of Chicago
| 4 years |
| Yi Lin | M | 55 |
The University of Chicago
| 2 years |
| Vanya Sagar | F | 49 | 3 years | |
| Adam Szalecki | M | - |
The University of Chicago
| 4 years |
| Jonathan Siegel | M | 54 |
The University of Chicago
| 2 years |
| Frank Lin | M | - |
The University of Chicago
| 4 years |
| Victor Ko | M | - |
The University of Chicago
| 4 years |
| David McReynolds | M | - |
The University of Chicago
| 4 years |
| Daniel Anthony Dittler | M | - |
The University of Chicago
| 2 years |
| Evan Marks Kominsky | M | - |
The University of Chicago
| 2 years |
| Eric Baer | M | - |
The University of Chicago
| 2 years |
| Joo Ryung Kang | F | - |
The University of Chicago
| 3 years |
| Bo Lars Erik Verneholt | M | 56 |
The University of Chicago
| 1 years |
| Igor Zomb | M | - |
The University of Chicago
| 1 years |
| David J. Slump | M | 55 |
The University of Chicago
| 2 years |
| Regan Hindman | M | - |
The University of Chicago
| 2 years |
| Matthew Brian Gooch | M | - |
The University of Chicago
| 2 years |
| Lauren Michelle MacIntosh | F | - |
The University of Chicago
| 4 years |
| Catherine J. Cusack | F | - |
The University of Chicago
| 2 years |
| Hong Duan | M | 60 |
The University of Chicago
| 2 years |
| Edmond Fong | M | - |
The University of Chicago
| 2 years |
| Steven T. Brannon | M | - |
The University of Chicago
| 2 years |
| Sheri Petras | F | 60 |
The University of Chicago
| 2 years |
| Atsushi Katayama | M | - |
The University of Chicago
| 2 years |
| Christopher Keith Polk | M | 44 |
The University of Chicago
| 3 years |
| Seungah Jeong | F | - |
The University of Chicago
| 4 years |
| Colin Carrier | M | - |
The University of Chicago
| 4 years |
| Sara Jones | M | - |
The University of Chicago
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philip Ashton-Rickardt
- Personal Network
